Inhibrx Biosciences Beats Earnings

Inhibrx Biosciences (NASDAQ:INBX), a clinical-stage biotechnology company specializing in novel biologic therapies, released its second quarter 2025 earnings on August 13, 2025. The most significant news from the release includes a narrower-than-expected GAAP net loss per share and GAAP revenue of $1.3 million, above analyst expectations due to a one-time licensing event. The company reported GAAP earnings per share of $(1.85), outperforming the consensus GAAP estimate of $(2.76), and posted GAAP revenue of $1.3 million, compared to GAAP estimates of zero. The quarter reflects progress in operational cost containment and clinical pipeline advancement following a major divestiture and corporate restructuring in 2024. Source: Analyst estimates for the quarter provided by FactSet. Inhibrx Biosciences develops antibody-based drug candidates using its proprietary protein engineering platforms. Its focus is on generating therapies that target diseases with unmet medical needs, primarily in oncology. The business is structured around advancing two lead clinical candidates: ozekibart (a type of engineered antibody therapy, INBRX‑109) and INBRX‑106, as well as earlier-stage discovery programs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool